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Abstract 25 
Antimicrobial resistance is one of the leading threats to society. The increasing burden of 26 
multidrug-resistant Gram-negative infection is particularly concerning as such bacteria are 27 
demonstrating resistance to nearly all currently licensed therapies. Various strategies have 28 
been hypothesised to treat multidrug-resistant Gram-negative infections including: targeting 29 
the Gram-negative outer membrane; neutralization of lipopolysaccharide; inhibition of 30 
bacterial efflux pumps and prevention of protein folding. Silver and silver nanoparticles, 31 
fusogenic liposomes and nanotubes are potential strategies for extending the activity of 32 
licensed, Gram-positive selective, antibiotics to Gram-negatives. This may serve as a strategy 33 
to fill the current void in pharmaceutical development in the short-term. This review outlines 34 
the most promising strategies that could be implemented to solve the threat of multidrug-35 
resistant Gram-negative infections.  36 
 37 
Introduction  38 
There is a drastic need for innovative therapeutic solutions that selectively target multi-drug 39 
resistant Gram-negative infections. This can be attributed to resistance to nearly all 40 
conventional antibiotics used clinically, and a lack of effective antibiotics in reserve. Gram-41 
negative bacteria, particularly: Pseudomonas aeruginosa, Escherichia coli, Klebsiella 42 
pneumoniae and Acinetobacter baumannii, are an ever-increasing threat to health and 43 
particularly that of hospitalized patients who commonly are immunocompromised, have co-44 
morbidities and are less able to fight infection [1]. Recently, emphasis has been placed on the 45 
rapid detection of specific, causative antimicrobial resistant strains. This has catalysed the 46 
drive to develop pathogen-specific, narrow spectrum antimicrobials. This change in focus 47 
from broad-spectrum microbial annihilation to more targeted therapy, acknowledges the 48 
major contribution empirical prescribing has on increasing drug resistance, and its impact on 49 
beneficial human microbiota [2].   50 
 51 
Nosocomial infections are a major contributor to healthcare associated infections and 52 
antimicrobial resistance. Approximately 20-40% are attributed to transfer of commensal 53 
microorganisms from the skin of healthcare workers to patients or even the patients’ own 54 
commensal flora [3]. Healthcare associated infections affect approximately 4.1 million 55 
patients annually within the European Union. They are a major contributor to morbidity 56 
causing 37, 000 deaths annually and a further 100,000 deaths in those with co-morbidities 57 
[4]. In terms of antimicrobial resistant infections, recent UK government reports estimate that 58 
these contribute to around 25,000 deaths annually in Europe alone [5]. 59 
 60 
Gram-negative bacteria are a particular problem due to multiple inherent resistance 61 
mechanisms, most notably the presence of a lipopolysaccharide (LPS) outer membrane and 62 
efflux pumps [6]. As a result of improper and overuse of antimicrobials, the resistance rates 63 
to current therapeutic agents have increased to serious levels. This dilemma has attracted the 64 
attention of scientists, the general public, health authorities and politicians. It is now 65 
recognized as a considerable global health problem [3]. As mentioned, the significant lack of 66 
newly licensed antimicrobial pharmaceuticals translating from the laboratory to patients is 67 
concerning. In the past 25 years, only two new cephalosporin-beta-lactamase inhibitor 68 
combinations- ceftolozane/tazobactam in 2014 and ceftazidime/avibactam in 2015 have been 69 
approved to treat systemic bacterial infections caused by multi-drug resistant Gram-negative 70 
bacteria [7]. There are a multitude of reasons for the decline in antimicrobial drug 71 
development, most notably the high financial commitment and time required for developing 72 
and registering a new drug. On average it costs approximately $800 million to introduce a 73 
new drug to market with development times normally in excess of 10 years. Parallel to this, 74 
the pharmaceutical industry has focused over the past 30 years on the more financially 75 
rewarding novel therapies for chronic diseases such as diabetes and cardiovascular disorders. 76 
These products are likely to be required as lifetime treatments in contrast to antibiotics that 77 
are most commonly short-term acute treatments (typically 5- 14 days) [8]. Other contributing 78 
factors include clinical trial requirements, particularly the challenge of proving novel 79 
therapies produce greater clinical outcomes compared to existing products, and that they are 80 
sufficiently safe for use. Pharmaceutical companies also express reservations about future 81 
resistance development that may reduce drug longevity [9][10]. In order to increase the 82 
approval and registration of new antimicrobials, the US Food and Drug Administration have 83 
indicated that it may be ready to alter its strict clinical-trial requirements and reassess the 84 
antimicrobial approval regulations in order to increase the potential availability of novel 85 
treatments [11]. The primary barriers to overcome, as will be discussed further in this review, 86 
include the specific targeting of Gram-negative bacteria in order to produce selective 87 
antibiotics that are suitable candidates for clinical trials and transition from the lab bench to 88 
the clinic.  89 
 90 
The Gram-negative outer membrane as a barrier to therapy 91 
I. Bacterial cell wall structure 92 
Understanding the mechanisms that govern Gram-negative bacterial resistance requires a 93 
fundamental appreciation of their cell morphology. The unique structure of the outer 94 
membrane of Gram-negative bacteria plays an important role, providing an additional layer 95 
of mechanical protection, without affecting the selectivity or exchange of material needed for 96 
bacterial survival [12]. The Gram-negative cell wall is composed of an outer LPS membrane 97 
and an inner cytoplasmic membrane. A thin layer of peptidoglycan and lipoproteins exist 98 
within the periplasmic space. The inner cell membrane is composed of a phospholipid 99 
bilayer, whilst the outer membrane consists of phospholipids on its interior leaflet and of LPS 100 
on its outer leaflet [13]. Porins and specialized transporters are also present within the outer 101 
membrane channels and mediate the influx of a variety of compounds including nutrients and 102 
minerals such as sugars, amino acids, phosphates and ions. Porins play an important role in 103 
bacterial metabolism and growth, and are therefore a valuable target for antimicrobial drug 104 
development [14]. Gram-negative bacteria continuously alter the expression and function of 105 
outer membrane porins hence this may affect the sensitivity of antimicrobial agents. Loss of 106 
or changes in porin amino acids could influence the ability or rate of entry of antibiotics and 107 
contribute to resistance. In contrast to Gram-negative bacteria, Gram-positive bacteria lack an 108 
outer membrane and are composed of a single lipid membrane surrounded by numerous 109 
interconnecting layers of peptidoglycan and lipoteichoic acid (Figure 1) [15]. Although 110 
Gram-positive bacteria possess a cell membrane, the lack of a protective outer membrane 111 
makes them more susceptible to antibiotics.  112 
 113 
 114 
II. Antimicrobial resistance mechanisms of Gram-negative bacterial cell wall  115 
The outer membrane of Gram-negative bacteria acts as a selective barrier by adding a 116 
hydrophobic lipid bilayer to the specific size-exclusion properties of porins. The outer 117 
membrane has the ability to block the entry of numerous toxic compounds and prevent the 118 
uptake of molecules with a molecular mass greater than 600 Daltons [16]. The influx of 119 
metabolites such as sugars, phosphates and hydrophilic molecules is mainly directed by 120 
porins. The continuous alteration in lipid or protein composition of the outer membrane leads 121 
to drug-resistance. This involves the increasing of outer membrane hydrophobicity, changing 122 
porin specificity or increasing the number and efficacy of efflux pumps [17].  123 
 124 
Reducing the negative charge of LPS within the bacterial outer membrane is one of the key 125 
strategies employed by Gram-negative bacteria to negate the action of membrane active 126 
cationic antimicrobials, such as chlorhexidine and cationic antimicrobial peptides. This is 127 
achieved via the addition of positively charged residues such as aminoarabinose and 128 
galactosamine sugars to LPS or by the removal of negative charged moieties. This 129 
modification leads to increased bacterial survival as demonstrated by both Pseudomonas 130 
aeruginosa and Francisella novicida after exposure to the cyclic cationic lipopeptide 131 
polymyxin B [18]. Amines are also harnessed by Gram-negatives to increase LPS membrane 132 
cationicity as demonstrated by Salmonella typhimurium which increases tolerance to 133 
polymyxin B by conjugating phosphoethanolamine to one of the phosphate groups present 134 
within outer membrane lipid A [19]. Bacteria are also able to remove anionic phosphate 135 
groups to reduce the overall anionic surface charge of LPS, proven by the removal of the 4′-136 
phosphate group from lipid A in Helicobacter pylori. This results in increased resistance to 137 
membrane active cationic antimicrobial peptides [20]. Phospholipids present in the Gram-138 
negative outer membrane are also susceptible to modification. Salmonella typhimurium has 139 
the ability to increase the levels of outer membrane glycerophospholipids resulting in 140 
increased membrane hydrophobicity and reducing the permeability of charged, water soluble 141 
molecules [21].   142 
 143 
Alteration of outer membrane porins prevent intracellular diffusion of small hydrophilic 144 
antibiotics such as beta-lactams, tetracycline, chloramphenicol and fluoroquinolones. 145 
Research has revealed that functional changes in porins are directed by specific mutations in 146 
a variety of pathogens, including Escherichia coli, Pseudomonas aeruginosa and Neisseria 147 
gonorrhoeae [14][22]. A relatively minor change in porin structure can have a significant 148 
effect on functionality. For example in Enterobacter aerogenes, substitution of glycine with 149 
aspartate within the peptide structure of its porin, results in a narrower lumen, affecting 150 
intracellular cephalosporin transport and lowering susceptibility to antimicrobials [14]. 151 
 152 
Efflux pumps are membrane bound proteins that regulate the intracellular environment active 153 
transport mechanisms to extrude toxic compounds such as bile salts, fatty acids and heavy 154 
metals outside of bacterial cells [23]. They are important cellular machinery in increasing 155 
Gram-negative bacteria’s ability to resist diverse classes of antibiotics including beta lactams, 156 
aminoglycosides and fluoroquinolones via expulsion out of the cell. These antibiotics often 157 
target intracellularly hence their expulsion restricts activity. Eﬄux pumps also contribute to 158 
bacterial virulence and the formation of biofilms [24]. The resistance-nodulation-division 159 
family (RND), one of five families of bacterial efflux pumps, is the only one that is 160 
specifically implicated in Gram-negative bacteria. Other families of efflux systems are 161 
extensively spread across both Gram-positive and Gram-negatives [25]. RND efflux pumps 162 
are able to expel a wide range of antibiotics with a high degree of specificity. Both RND-163 
based efflux pumps in Pseudomonas aeruginosa, MexAB-OprM and MexXY-OprM, can 164 
expel tetracycline, fluoroquinolones, and chloramphenicol, whilst for beta-lactams and 165 
novobiocin, expulsion occurs via the MexAB-OprM system [24]. 166 
 167 
Strategies for extending therapeutic activity against Gram-negatives  168 
I. Antimicrobial peptides  169 
Antimicrobial peptides were first isolated by Dubos in 1939 from Bacillus bacteria derived 170 
from soil [26]. The amphipathic nature of most antimicrobial peptides proves advantageous 171 
for antimicrobial activity. The presence of hydrophilic and hydrophobic domains allows 172 
interaction with both lipid and phospholipid groups present in the bacterial cytoplasmic 173 
membrane [27].  The majority of antimicrobial peptides are cationic in character. These 174 
naturally occurring molecules mediate an innate immune response in a multitude of 175 
organisms [28]. They possess several optimal properties for therapeutic applications. Cationic 176 
antimicrobial peptides have the ability to bind to LPS and therefore negate the production of 177 
host pro-inflammatory cytokines [29]. Most cationic antimicrobial peptides exert their 178 
bactericidal action via targeting of bacterial membranes, resulting in membrane 179 
disintegration, cell lysis and death [28]. A variety of antimicrobial peptides demonstrate an 180 
ability to permeate bacterial cell membranes at low concentrations, inhibiting DNA 181 
replication and protein synthesis without altering membrane integrity [27]. For example, 182 
buforin-II binds to DNA and RNA without disrupting the bacterial cell membrane 183 
architecture [30]. Cationic antimicrobial peptides have great potential to fill the current void 184 
in antimicrobial drug development because of their selectivity for negatively charged 185 
microbial membranes compared to neutral sterol-rich mammalian forms. Antimicrobial 186 
peptides tend to demonstrate rapid bactericidal activity utilising multiple modes of extra- and 187 
intra-cellular action. They therefore have a reduced tendency to promote bacterial resistance 188 
compared to many currently licensed antimicrobials which tend to target only a single 189 
biomolecular mechanism. Antimicrobial peptides are already in clinical use and such 190 
examples include lysostaphin, polymyxin B and gramicidin S, demonstrating their potential 191 
for clinical translation and ability to fill the void in current antimicrobial drug development 192 
[31]. 193 
 194 
Polymyxins are a class of cationic cyclic lipopeptides, first discovered in 1947, isolated from 195 
the spore-forming bacteria Paenibacillus polymyxa present in soil. Polymyxin E (colistin) and 196 
polymyxin B are classified as narrow spectrum Gram-negative selective antibiotics. Their 197 
clinical use decreased in the 1970s due to concerns regarding nephro- and neuro-toxicity. 198 
Most recently there has been a revival in their potential clinical use and research has focused 199 
on the design of novel polymyxin derivatives with markedly lower mammalian toxicity and 200 
higher bactericidal activity [32]. The exact bactericidal mechanism of polymyxins has 201 
remained a topic for debate amongst researchers. It has been hypothesised that the protonated 202 
amino acids within the cyclic peptide structure of polymyxins, bind directly to the lipid A 203 
part of LPS present in the outer membrane of Gram-negative bacteria, facilitating insertion of 204 
hydrophobic motifs into the outer membrane. This enables the formation of pore-like 205 
aggregates thus increasing outer membrane permeability [33]. Polymyxin B, for example, has 206 
the ability to attach to the anionic surface of LPS in the outer membrane resulting in self-207 
promoted uptake into the periplasmic space and cytoplasmic membrane. It is more difficult 208 
for bacteria to generate resistance against such physical interactions as it would require 209 
reorganisation of vast areas of the membrane architecture. However, plasmid-borne resistance 210 
has been reported recently against colistin and this is concerning as colistin is typically 211 
considered a drug of last resort for Gram-negative infections [34]. The mcr-1 plasmid, 212 
identified in an Escherichia coli isolate present in a pig in China, encodes an enzyme that 213 
directs the addition of phosphoethanolamine to lipid A decreasing the anionic charge of the 214 
outer membrane. Whilst this addition has been elucidated previously, the fact that the process 215 
is mediated via a plasmid is crucially significant, as it will allow resistance to readily spread 216 
to other species. This discovery highlights the urgent need for investment to elucidate 217 
antimicrobial resistance mechanisms and for tailored therapies to combat these.  218 
 219 
Research into polymyxin-like molecules has been on-going, especially with regard to 220 
producing less toxic derivatives (nephro- and neuro-toxic) and compromising the integrity of 221 
the Gram-negative outer membrane barrier to increase the activity of existing antibiotics [35]. 222 
Structurally similar cyclic antimicrobial peptides are also of interest as future synthetic 223 
therapies as they possess increased serum stability relative to linear forms. They may also 224 
provide a basis for designing cost-effective, low molecular mass, anti-LPS compounds [36]. 225 
Cyclic peptide variants are synthesised by directly conjugating the two terminals of the 226 
primary amino acid sequence to form an amide bond, or via another form of linkage such as 227 
lactone or disulfide bonds. Generally, cyclic peptides are more effective than their linear 228 
analogues because of the structural rigidity that enables cyclic peptides to bind selectively to 229 
bacterial targets. They can also adapt an ordered amphipathic structure that allows them to 230 
insert deeper within the bacterial membrane, with extended action in vivo due to their 231 
increased stability to proteases [37].  Almost all known natural cyclic peptides display high 232 
antibacterial activity. For example, polymyxin B, colistimethate and gramicidin S show high 233 
bactericidal activity against Pseudomonas aeruginosa with minimum bactericidal 234 
concentrations of 0.125, 4 and 8 μg/ml respectively [38]. Despite their significant bacterial 235 
activity in vitro, many cyclic peptides are highly haemolytic and currently lack the bacterial 236 
selectivity required for clinical translation [39].  237 
 238 
II. Combinational antibiotic treatment for Gram-negative bacteria 239 
Synergistic therapy, a combination of two or more antibiotics, is a commonly employed 240 
strategy to resolve Gram-negative infections. In comparison to monotherapy, combination 241 
therapy takes advantage of the additive effects of multiple antimicrobial mechanisms for each 242 
drug therapy to lower the risk of resistance developing. Combination therapy has also been 243 
demonstrated to lower mortality and improve clinical outcomes. It is recommended for 244 
patients whose infection is suspected or confirmed to be multidrug-resistant Gram-negative 245 
bacteria [40]. Synergy between two or more antimicrobial agents means that the combined 246 
effect will be greater than their individual effects. Combination therapy allows lower 247 
prescribed doses of individual antimicrobials and shortens the duration of treatment reducing 248 
the risk of adverse side effects to the patient [41]. Generally each individual antibiotic 249 
employed varies with respect to their mode of action [42]. However, the use of multiple 250 
therapies does not come without risk. Combination therapy has been associated with an 251 
increase in nephrotoxicity, especially when prescribed in long term chronic infections. 252 
Another disadvantage is the increased complications associated with multiple treatment 253 
schedules [43]. A model combination therapy includes a broad-spectrum beta-lactam with an 254 
aminoglycoside, macrolide or fluoroquinolone for treatment of Pseudomonas infections [40]. 255 
A novel combination between cephalosporins and a beta-lactamase inhibitor has been 256 
recently approved [7]. A synergistic approach is a beneficial strategy that is available 257 
currently to reduce the burden of antimicrobial resistance, whilst efforts intensify to identify, 258 
design and test new antimicrobial therapies. 259 
 260 
III. The activity of silver against Gram-negative bacterial infection  261 
Silver has been known to protect against infection for over 2,000 years and continues to be 262 
used widely in many antimicrobial applications, especially within the biomaterial industry. 263 
Morones-Ramez and colleagues demonstrated that silver ions (Ag+) have a synergistic effect 264 
with beta-lactam, aminoglycoside and quinolone antibiotics against a variety of Gram-265 
negative bacteria. Silver has been shown to increase the production of reactive oxygen 266 
species, including hydroxyl radicals (OH•), increasing the permeability of the outer 267 
membrane to commonly employed antibiotics [44]. Silver also acts intracellularly to 268 
inactivate bacterial protein synthesis and enzymes responsible for a range of biochemical 269 
processes, including deoxyribonuclease and ribonuclease. Silver has also been implicated in 270 
DNA degradation and activation of cysteine proteases, namely the cysteine-dependent 271 
aspartate-directed proteases, which play an important role in bacterial cell apoptosis. Silver 272 
ion’s cationic properties bestow affinity for anionic minerals present in the host, such as 273 
chloride or phosphate, or proteins such as albumin. The complexes that form are inactivated 274 
by precipitation or deposit in tissue debris with the potential to cause toxicity. Problems such 275 
as these have led to questions regarding the safety and widespread use of silver for 276 
antibacterial applications. More recently studies have focused on improving silver’s ability to 277 
selectively target bacterial metabolic pathways via a silver nanoparticle system [45]. Silver 278 
nanoparticles have attracted interest in the development of new pharmaceutical products. 279 
They have been introduced into wound dressings, medical device coatings, and are 280 
increasingly utilized as drug delivery nanomaterials. Silver nanoparticle dressings, when 281 
compared to silver sulfadiazine cream, have been found to decrease wound-healing time and 282 
improve the clearance of bacteria from the infection site. Within medical devices, silver 283 
nanoparticles have been tested as novel coatings for catheters, which are typically liable to 284 
bacterial infections leading to complications such as device failure and sepsis. Furthermore, 285 
they have the potential to be administered as drug delivery platforms, acting as carriers for 286 
licensed antibiotics and enabling penetration of the Gram-negative outer membrane [46]. 287 
 288 
Specific methods to target Gram-negative pathogens 289 
As highlighted, the development of bacterial resistance towards existing antimicrobial agents 290 
has led to an urgent need for effective, alternative strategies. There is a necessity to develop 291 
novel classes of antibiotics and different methods to bypass current resistance mechanisms of 292 
Gram-negative bacteria [6]. There are multiple hypothesised mechanisms by which this can 293 
be achieved including: targeting membrane integrity by binding to LPS; interacting with the 294 
DsbA-DsbB enzyme system; or blocking the intracellular expulsion of antibiotics via 295 
inhibition of efflux pumps. Innovative drug delivery platforms are also considered to be 296 
“smart” approaches to enhance the efficacy of existing and future antibiotics. Genetic 297 
engineering of phage lytic enzymes is also a promising strategy with the potential to kill 298 
specific Gram-negative bacterial strains. Whilst all these approaches hold great promise, their 299 
potential for pharmaceutical scale-up and related regulatory barriers have to be considered 300 
early in the drug development process. Additionally, the high cost and the requirement to 301 
prove quality, efficacy and safety considerations are the main reason behind clinical trial 302 
failure and cessation of antimicrobial drug development [47]. Despite this, we will look 303 
further at the most promising approaches to resolving the clinical and resistance barriers that 304 
govern Gram-negative bacterial infection.  305 
 306 
I. Negating the biological effects of Gram-negative lipopolysaccharide 307 
As well as being the major constituent of the outer membrane, LPS signals bacterial invasion 308 
and triggers an aggressive host immune response resulting in the release of pro-inflammatory 309 
mediators, cytokines, chemokines, and lipoproteins [48]. Lipid A is the hydrophobic portion 310 
of LPS that is chiefly responsible for biological toxicity. Within the outer membrane it 311 
protects Gram-negative bacteria from host immune defences by forming a gel-like layer of 312 
low fluidity. This layer limits the influx of hydrophobic solutes into the cell including many 313 
antibiotics [49]. Excessive host response to LPS causes organ dysfunction, septic shock and 314 
can even result in death. Antibiotics currently used to treat Gram-negative infections 315 
exacerbate the immune crisis by causing bacterial cell lysis, resulting in the release of 316 
significant amounts of LPS into the systemic circulation and creating an infection that is 317 
difficult to treat effectively [50]. The risk of these events requires consideration prior to 318 
initiation of empirical therapy as demonstrated in 2011, when the European Union witnessed 319 
a haemolytic uremic syndrome outbreak caused by Shiga toxin-producing Escherichia coli 320 
O104:H4. Treatment with antibiotics such as quinolones enhanced the release of its virulence 321 
factors, including LPS, resulting in multiple deaths [51]. 322 
 323 
The severity of the host response is mediated by plasma lipoproteins and the LPS-binding 324 
receptor CD14 that appears on the surface of host macrophages and neutrophils [52]. 325 
Examples of plasma lipoproteins include lipopolysaccharide-binding protein (LBP), 326 
bactericidal/permeability-increasing protein (BPI), phospholipid transfer protein and 327 
antimicrobial proteins secreted by neutrophils. Their binding to LPS causes a variety of 328 
cellular effects [53].  Both soluble LBP and CD14 are present in the blood and are known to 329 
enhance the effects of bacterial LPS. When LPS binds to LBP, the complex is recognized by 330 
host CD14 receptors that in turn activate the production of pro-inflammatory cytokines and 331 
type-I interferon, leading to local and systemic inflammatory reactions [52]. In contrast, BPI 332 
binding to LPS is thought to be inhibitory and therefore beneficial in preventing an 333 
exaggerated immune response. Recombinant and modified forms of BPI have been assessed 334 
in clinical trials in patients with severe sepsis or septic shock. For example, recombinant BPI 335 
(rBPI21) is composed of the amino-terminal half of naturally occurring BPI and possesses 336 
antibacterial and anti-LPS effects. When one amino acid cysteine residue of BPI is replaced 337 
with alanine biological stability is significantly improved without affecting the neutralizing 338 
properties of BPI [54]. This highlights how naturally occurring biomolecules can be altered 339 
synthetically to improve pharmacological and pharmaceutical properties. If harnessed 340 
correctly it will enable a wealth of potential therapies to be explored. 341 
 342 
Throughout history nature has been the most significant source of antimicrobial therapies and 343 
there has been an increased focus on identifying novel molecules of interest from natural 344 
sources. Limulus anti-LPS factor (LALF) is an example of a small cyclic basic peptide found 345 
in haemocytes of marine chelicerates, demonstrating a strong affinity to LPS. It shows the 346 
ability to neutralize LPS by inhibiting the inflammatory cytokine tumour necrosis factor-347 
alpha produced as a result of LPS stimulation of the immune response. The amino acid 348 
sequence that is responsible for LALF activity is found between amino acids 31 and 52 349 
within the primary peptide sequence. The synthetic peptides derived from LALF 31-52 bind 350 
to LPS with high affinity and inhibits binding of LPS to LBP in a dose-dependent manner. 351 
The protective effect of LALF has been shown in vivo via Escherichia coli and Pseudomonas 352 
aeruginosa sepsis models in mice, with administration of LALF resulting in extended life 353 
span and decreased mortality [55].  354 
 355 
II. Targeting disulfide bond formation by the bacterial DsbA-DsbB enzyme system of 356 
Gram-negative bacteria 357 
The folding, stability and activity of a multitude of proteins in prokaryotic and eukaryotic 358 
cells are attributed to disulfide bonds formed between pairs of cysteines within peptide 359 
monomer units. Formation of a covalent disulfide bridge, via oxidation of sulfhydryl groups 360 
(-SH) on corresponding cysteines, is important for the stabilization of the protein tertiary 361 
structure. In bacteria disulfide bond formation is mediated by the DsbA-DsbB enzyme 362 
system. The Gram-negative bacterial genotype encodes for a diversity of cysteine-based 363 
disulfide bound proteins that are responsible for many bacterial virulence factors including 364 
toxins, adhesins, flagella, fimbriae, and secretion systems [56]. For example, Escherichia coli 365 
has around 300 proteins consisting of even numbers of cysteine residues that require DsbA 366 
for folding [57]. It is hypothesized therefore that inactivation of enzymes that mediate the 367 
creation of disulphide bonds in such proteins will disturb the stability and activity of related 368 
virulence factors.  369 
 370 
In Gram-negative bacteria the periplasmic enzyme DsbA is a member of the thioredoxin 371 
family and oxidizes complementary pairs of cysteines to form disulfide bonds during their 372 
movement through the cytoplasmic membrane into the cell envelope (Figure 2) [56][58]. The 373 
resulting reduced active site cysteine of DsbA is re-oxidised by the inner membrane partner 374 
protein DsbB, restoring DsbA’s activity. The subsequent reduced DsbB is reoxidized and 375 
restored using the oxidizing power of membrane-embedded quinones [59]. A number of 376 
molecules have been found that disrupt this enzymatic pathway. Landeta and colleagues 377 
discovered during screening of compounds that 4,5-dichloro-2-(2-chlorobenzyl)-3(2H)-378 
pyridazinone inhibits disulfide bond formation in Escherichia coli by blockage of the DsbB 379 
enzyme in vitro. This compound was shown to bind covalently to the DsbB-DsbA system and 380 
inhibit Escherichia coli growth. 4,5-dichloro-2-(2-chlorobenzyl)-3(2H)-pyridazinone was 381 
also shown to inhibit DsbB enzymes in eight of nine tested Gram-negative pathogenic 382 
bacteria [56]. Since the DsbA-DsbB system is responsible for disulfide bond formation in 383 
Gram-negatives, it is an essential process for the correct folding and assembly of multiple 384 
virulence factors and the bacterial cell envelope. This makes it a key target for the 385 
development of new drugs to tackle Gram-negative infection. These compounds also exhibit 386 
synergistic effects with a variety of antibiotics including beta‐lactams, kanamycin, 387 
erythromycin, novobiocin, and ofloxacin [60].  388 
 389 
III. Inactivating Gram-negative efflux pumps  390 
RND efflux pumps in Gram-negative pathogens play an important role in bacterial resistance 391 
to a wide range of antibiotics, and so they are considered as a valuable field for development 392 
of efflux pump inhibitors (EPI) for use in combination therapy. EPIs are envisaged to 393 
increase the intracellular retention time and therefore efficacy of co-administered antibiotics 394 
[61]. As outlined previously, RND pumps in Gram-negative bacteria are responsible for 395 
exporting drugs and other toxic cations out of the cell. Their expression is upregulated in 396 
response to external stress factors, including reactive oxygen species, cell membrane injury or 397 
ribosome blocking agents [62]. The main RND efflux pumps expressed in Gram-negatives 398 
are AcrAB-TolC in Escherichia coli and MexAB-OprM in Pseudomonas aeruginosa. 399 
Located within the inner cell membrane their efflux action is mediated by bacterial 400 
periplasmic adaptor proteins and an outer membrane channel (Figure 3). If an antimicrobial 401 
agent successfully transverses the outer membrane via diffusion or porin channels, it enters 402 
the periplasmic space. Once the antibiotic is in the periplasmic space, it binds to the 403 
substrate-binding pocket of periplasmic adaptor proteins. The drug is actively transported to 404 
the outer membrane channel and into the extracellular environment. Pseudomonas 405 
aeruginosa PAO1 alone has 12 different RND eﬄux systems demonstrating the varying 406 
complexity of bacterial efflux systems and the significant contribution they have in Gram-407 
negative resistance [61]. 408 
 409 
The physicochemical properties of the antibiotic molecule also determines its extrusion rate 410 
by efflux pumps. RND pumps are mainly composed of an amino acid sequence with 411 
lipophilic side chains. Small hydrophilic molecules, which move rapidly through porins, 412 
possess a low efflux rate limiting their expulsion from the periplasmic space. However in 413 
Pseudomonas aeruginosa, porins only allow a much slower entry of small molecules and so 414 
efflux pumps can rapidly export them out of the cell. RND pumps also effectively efflux 415 
more lipophilic and larger molecules, as they diffuse slowly through the hydrophobic layer of 416 
the outer membrane. The rate of influx and active efflux of a drug can influence the minimum 417 
inhibitory concentration (MIC) of an antibiotic in vitro [63].  418 
 419 
Researchers have attempted to inhibit RND efflux pumps to restore the activity of antibiotics 420 
previously deemed unusable due to the development of resistance [62]. Peptidomimetic 421 
molecules were the first synthesized EPIs. Phenylalanyl-arginyl-β-naphthylamide is a 422 
peptidomimetic compound that inhibits the levofloxacin efflux in Pseudomonas aeruginosa 423 
overexpressed with MexAB-OprM efflux pumps. It achieves this by directly competing with 424 
the antibiotic sites on MexAB-OprM [21]. Another novel EPI is the pyranopyridine 425 
derivative, MBX2319, which increases Escherichia coli sensitivity to ciprofloxacin, 426 
levofloxacin and piperacillin by inhibiting AcrAB-TolC efflux pumps. Peptidomimetic EPIs 427 
often possess cidal antibacterial activity alone but are more likely to form an important role 428 
within future clinical strategies as part of combination therapy [63]. 429 
 430 
Methods to extend the spectrum of activity of existing narrow spectrum Gram-positive 431 
antibiotics to Gram-negatives 432 
The majority of antimicrobial agents, especially within the field of antimicrobial peptides, 433 
characterized in the laboratory setting are commonly more active against Gram-positive than 434 
Gram-negative bacteria [28].  A similar scenario exists clinically with a worrying lack of 435 
effective treatment options in reserve.  Of greatest significance is the increase in resistance 436 
attributed to the Gram-negative pathogens Pseudomonas aeruginosa, Escherichia coli, 437 
Klebsiella pneumoniae and Acinetobacter baumannii, due in part to a lack of available, 438 
effective narrow spectrum Gram-negative selective antibiotics. The majority of antibiotics 439 
reserved for resistant Gram-positive infection have no activity against Gram-negatives as 440 
they are incapable of crossing the Gram-negative LPS outer membrane barrier. The critical 441 
need for urgent action in the licensing and availability of effective antimicrobials to treat 442 
Gram-negative infections clinically has led researchers to concentrate their efforts on 443 
uncovering new and effective drug delivery systems to expand and target the spectrum of 444 
activity of currently licensed antibiotics. Various platforms, including fusogenic liposomes 445 
and nanotubes are in development. They represent a novel approach to tackle the current 446 
deficit in Gram-negative antibiotics and hope to rapidly extend the currently available 447 
antibiotic library using regulatory approved Gram-positive drugs.  448 
 449 
I. Fusogenic liposomes 450 
Liposomes are small vesicular systems composed of an amphipathic phospholipid bilayer 451 
with an aqueous interior core. They are attractive from a drug delivery perspective due to 452 
their varying hydrophobic (membrane) and hydrophilic (core) architecture that allows the 453 
incorporation of both hydrophobic and hydrophilic drugs, including a vast range of 454 
antibiotics. Liposomal vesicles vary widely in diameter from 0.025 to 2.5 μm [64] and 455 
demonstrate high biocompatibility and biostability resulting in prolonged circulation life [65]. 456 
Liposomes are promising molecules for antimicrobial drug delivery as the amphipathic 457 
properties of the phospholipids enable strong interactions with the bacterial membranes and 458 
enhance the release of the encapsulated drugs across them [66]. Interactions between 459 
liposomal vesicles and bacterial membranes occur via multiple mechanisms, including 460 
physical adsorption, lipid exchange and fusion. Liposomal-cell interactions are influenced by 461 
the composition of the bacterial cell membrane, the exterior structure of liposomal carrier and 462 
the biological environment [67].  463 
 464 
Fusogenic liposomes are a variation on standard liposomal formulations consisting of 465 
inactivated Sendai virus envelope components (mainly for targeting of eukaryotic cells) or 466 
nonviral vectors involving the inclusion of specific lipids, for example amphiphilic 467 
derivatives of cholesterol including cholesterol hemisuccinate, that increase fluidity of 468 
liposomal vesicles to promote weakening of biological membranes. They demonstrate an 469 
enhanced ability to fuse with cell membranes, mixing with their lipids, resulting in delivery 470 
of vesicular contents into the cytoplasm [64]. They are promising as potential molecules to 471 
transverse the Gram-negative outer membrane, enabling delivery of antibiotics such as 472 
vancomycin to the periplasmic space. Vancomycin is a glycopeptide antibiotic with a 473 
complex chemical structure and a high molecular weight (approximately 1450 daltons). It is 474 
used clinically in the treatment of severe, multi-drug resistant Gram-positive infections. It 475 
exerts a bactericidal effect by inhibiting the synthesis of peptidoglycan, the major component 476 
of the bacterial cell wall [66]. The Gram-negative outer membrane is impermeable to 477 
vancomycin macromolecules, therefore they are intrinsically resistant. Encapsulation of 478 
vancomycin within fusogenic liposomes composed of dioleoylphosphatidylethanolamine, 479 
dipalmitoylphosphatidylcholine and cholesterol hemisuccinate enables delivery to the 480 
periplasmic space therefore allowing activity against Gram-negative bacteria. In a study by 481 
Nicolosi and collagues, non-encapsulated vancomycin demonstrated high MIC values, 482 
greater than 512 μg/ml for Escherichia coli and Acinetobacter baumannii, which reduced 483 
significantly to 6 μg/ml upon inclusion within this liposomal platform [68]. This 484 
demonstrates the potential of liposomal drug delivery platforms to extend the therapeutic 485 
efficacy of narrow spectrum Gram-positive therapies. 486 
 487 
II. Carbon and peptide nanotubes 488 
Nanotechnologies, for example nanotubes, are at the forefront of research to tackle the most 489 
difficult diseases in human and animal health. Nanotubes are materials consisting of hollow 490 
cylindrical tubes with nanoscale morphology [69]. Organic-based nanotubes are attracting 491 
increased attention as therapeutic applications, with researchers attempt to synthetically 492 
replicate the nanoscale architectures of biomolecules such as DNA. Two of the most 493 
promising nanomaterial formats are carbon and peptide-based systems [70]. Due mostly to 494 
their increased structural strength and biological stability, carbon nanotubes have attracted the 495 
attention for a range of applications throughout nanomedicine [71]. They can be formed by 496 
coiling a single layer of graphene sheet to form single-walled carbon nanotubes, or by rolling 497 
several layers to form multi-walled carbon nanotubes. The diameter of single-walled carbon 498 
nanotubes varies from 0.4 to 3.0 nm with their length ranging from 20 to 1000 nm. Their 499 
formation is driven by van der Waals intermolecular interactions increasing their structural 500 
flexibility. Multi-walled carbon nanotubes are easier to manufacture than single-walled 501 
variants, possessing an outer diameter ranging from 2 to 100 nm and inner diameter of 1 to 502 
3 nm respectively. However, their length of 1 to several micrometres limits their structural 503 
flexibility compared to single wall forms. Non-functionalized carbon nanotubes are insoluble 504 
in aqueous physiological media making formulation difficult and some concerns do exist 505 
regarding their safety in humans. For example, some studies have demonstrated toxicity to 506 
mammalian cells including mediators of the immune response such as macrophages due 507 
mainly to their high hydrophobic character [72].  508 
 509 
Carbon nanotubes also lack homogeneity in terms of their size (diameters, length) this makes 510 
it difficult to effectively link the type of formulation (e.g. suspension) and concentrations to 511 
biological activity [73]. For future antimicrobial drug delivery purposes, carbon 512 
nanostructures will likely require functionalization before attachment of a drug and this can 513 
prove difficult due to the lack of chemical versatility provided by the rigid carbon-carbon 514 
covalent bond. Covalent and noncovalent surface functionalization can be performed on the 515 
synthesized carbon nanotubes facilitating the conjugation of antimicrobial agents such as the 516 
antifungal amphotericin B [69]. Specific antibacterial activity has also been demonstrated for 517 
carbon nanotubes against Gram-negative pathogens including Escherichia coli. Single walled 518 
nanotubes are particularly effective due to their smaller diameter and therefore increased 519 
ability to penetrate the cell wall. Carbon nanotubes display inherent antibacterial activity via 520 
physical disruption of Escherichia coli’s bacterial cell membrane and oxidation of bacterial 521 
glutathione resulting in oxidative stress and cell death [74]. The addition of hydroxyl (-OH) 522 
and carboxylic acid (-COOH) groups to the surface of single-walled carbon nanotubes has 523 
also been shown to enhance antimicrobial activity against Gram-positive and Gram-negative 524 
bacteria. This is due to the formation of cell-nanotube aggregates and subsequent cell wall 525 
lysis and DNA release [73]. Interestingly multi-walled carbon nanotubes do not display 526 
similar efficacy due to increased length and a reduced ability to aggregate with bacterial cells 527 
[74]. To date the majority of antibacterial carbon nanotube strategies are broad spectrum in 528 
focus including coating with copper to eradicate Escherichia coli and Staphylococcus aureus 529 
[75]. As the Yang group confirmed, neither the difference in cell wall structures between 530 
Gram-negative and Gram-positive isolates nor the bacterial cell shape (cocci or rods), alter 531 
the effectiveness of the single-walled carbon nanotubes [73]. Carbon nanotube research has 532 
therefore been unable to selectively target Gram-negatives but the platform holds great 533 
promise in the delivery of current and future drug molecules across the outer membrane 534 
barrier.  535 
 536 
Peptide-based nanomaterials have also received attention from researchers in the past decade 537 
due to their chemical and functional versatility.  Peptide nanomaterials have many advantages 538 
over current synthetic-based materials utilised throughout healthcare. Peptides possess vast 539 
chemical flexibility attributable to variation of the amino acid R-group. As a result they can 540 
be utilised to create nanomaterials with very specific functionalities and have the potential to 541 
conjugate to a variety of molecules including antimicrobial drugs. Amino acids are the 542 
building blocks of peptides, proteins and tissues, existing throughout the body. The primary 543 
amino acid sequence of peptides can be modified in order to drive self-assembly to 544 
nanomaterials structures (nanofibers, nanotubes) in response to a range of physiochemical 545 
stimuli (pH, temperature, ionic strength, presence of specific enzymes). Self-assembling 546 
peptide platforms are gaining increasing interest as potential future antimicrobial 547 
nanotherapies. The properties required for peptide assembly to occur are similar to those that 548 
confer antimicrobial activity to the peptide, namely hydrophobic and electrostatic interactions 549 
[76].  550 
 551 
Some of the most successful approaches to target Gram-negative bacteria have focused on 552 
utilising self-assembling linear and cyclic peptides. This is due to their ability to target 553 
bacterial cell membranes and their structural similarities to naturally occurring polymyxins 554 
[77]. Cyclic peptide nanotubes are primarily hexamers or octamers, composed of alternating 555 
amphiphilic D- and L-amino acid residues, for example L-tryptophan and D-leucine. They 556 
self-assemble into flat ring-shaped structures, with different channel diameters ranging from 557 
0.2 to 1.3 nm [78]. Cyclic peptides can arrange into tubular open-ended structures via 558 
intermolecular interactions including hydrogen bonding. When adsorbed onto bacterial cell 559 
membranes, they have demonstrated selective membrane permeabilization and lysis of Gram-560 
positive (Staphylococcus aureus) and Gram-negative (Escherichia coli) cells compared to 561 
mammalian cells [79]. Cyclic peptide nanotubes have great potential as synergistic 562 
antimicrobial therapies when used in conjunction with conventional antibiotics. They act as 563 
delivery systems increasing antibiotic concentration, hence antimicrobial activity, within the 564 
bacterial cell [80].  565 
 566 
III. Targeting Gram-negative pathogens with an engineered phage lytic enzyme 567 
Phages are viruses that demonstrate activity against bacterial cells, including multi-drug 568 
resistant Gram-negatives.  They were originally studied as potential antimicrobial therapies in 569 
the United States in the 1930s and more extensively over the past 80 years in Eastern Europe 570 
[81]. Phages have been reported to be effective in resolving a variety of infections including: 571 
skin infections caused by Pseudomonas, Staphylococcus, Proteus, Escherichia coli, surgical 572 
wound infections, staphylococcal lung and pleural infections, and Pseudomonas aeruginosa 573 
infections in cystic fibrosis patients [82]. There are several reports that show that enzymes 574 
isolated from phages, termed lysins, may be considered as therapeutic agents. Lysins 575 
produced by bacteriophages are recombinant proteins designed to make “holes” in the cell 576 
wall of a bacterium causing rapid cell lysis and death [83]. Until recently the action was 577 
mainly restricted to Gram-positive bacteria. Applying the same strategy to Gram-negative 578 
pathogens was considered difficult because their enzymatic target, peptidoglycan, is 579 
sequestered beneath a protective outer membrane where the lytic enzyme cannot reach. 580 
However, research by Lukacik and colleagues demonstrated that phage lytic enzymes can be 581 
engineered to cross the outer envelope of Gram-negative bacteria. This is achieved by 582 
production of hybrid lysins that have the ability to travel across the outer membrane of Gram-583 
negatives such as Yersinia pestis and pathogenic Escherichia coli strains, breaking down the 584 
peptidoglycan layer in the periplasm. Hybrid lysin demonstrated cidal action against these 585 
strains without disrupting the outer membrane. [84]. Variations to this theme also exist. 586 
Artilysins are engineered lysins conjugated to cationic peptides extending the bactericidal 587 
activity against Gram-negatives, including Pseudomonas aeruginosa and Acinetobacter 588 
baumannii. The inclusion of a cationic peptide disturbs the LPS outer membrane layer, 589 
allowing lysins to enter the periplasmic space resulting in degradation of peptidoglycan, cell 590 
lysis and death [83].   591 
 592 
Conclusions 593 
The increasing resistance of Gram-negative bacteria to a multitude of currently available 594 
antibiotics requires urgent action. Research regarding novel alternative therapies has focused 595 
on a variety of strategies, many of which have failed to progress successfully to clinical 596 
translation and utilisation for patient benefit. The majority of approaches have focused on 597 
extending the spectrum of activity of current Gram-positive targeting molecules to Gram-598 
negatives. Whilst this warrants attention and should not be dismissed, a narrow spectrum, 599 
species targeted approach is likely to be more beneficial with greater consideration of a 600 
healthy commensal microbiota. This approach requires increased ability to rapidly diagnose 601 
and detect specific causative microorganisms implicated infection so that optimal targeted 602 
therapy can be provided. The research strategies outlined in this review contribute to 603 
expanding potential future therapeutic options at a time when clinical choices are becoming 604 
increasingly limited. Currently there are clinical trials involving several antimicrobial 605 
peptides. This diverse group of molecules display selective antimicrobial activity against 606 
bacteria relative to mammalian cells. Whilst in vitro results have demonstrated promise, in 607 
vivo toxicity and biostability has restricted their progress. Other successful laboratory 608 
research, involving attenuation of LPS and inhibition of RND efflux, display promise in 609 
limiting the severe clinical implications of Gram-negative infection. Indeed many compounds 610 
that display a LPS neutralizing ability may be suitable for future clinical trials as they have 611 
demonstrated both in vitro and animal model efficacy. RND eﬄux pumps inhibitors are 612 
attractive compounds that improve the clinical efficacy of antibiotics in resistant bacterial 613 
pathogens. Understanding biochemical pathways in Gram-negative bacterial metabolism and 614 
resistance will complement the development of novel and tailored therapies. For example, 615 
targeted inhibition of DsbA-DsbB enzymes prevents disulfide bond formation and the 616 
formation of stable protein tertiary structures within bacterial virulence factors. Despite the 617 
promise shown by such an approach no compounds have yet transferred from the laboratory 618 
into clinical trials highlighting the importance of pharmaceutical formulation in advancing 619 
molecular targets. Improving antibiotic delivery using liposomes or nanotubes is another 620 
encouraging approach to extend therapeutic activity of conventional antibiotics against Gram-621 
negatives. There is real hope for progress within this area especially as liposomal approaches 622 
have successfully resulted in licensed formulations for a variety of drugs including the 623 
antifungal amphotericin B. Engineered lysins have proven to be a truly alternative approach 624 
resulting in a new class of antimicrobials. However, this approach still requires further 625 
investigation particularly with regard to patient safety and their likelihood to develop 626 
resistance.  627 
 628 
Future Perspectives 629 
As outlined, the need to eradicate multi-drug resistant bacteria and reduce the impending 630 
threat of resistance is an increasing challenge not only for the scientific community but 631 
society as a whole. It is everyone’s responsibility to use existing antibiotics wisely in order to 632 
delay an antimicrobial crisis and allow time for the development of effective novel 633 
compounds. The research community has a key role to play in breaking down the microbial 634 
processes that lead to resistance and developing strategies to combat such biomolecular 635 
pathways. Collaboration is key for successful clinical translation. There is widespread 636 
acceptance that a targeted isolate-specific approach to eradicate multi-drug resistant bacteria 637 
is necessary to prevent treatment failure and risk of an increased number of antimicrobial 638 
resistant strains. Some of the strategies outlined in this review provide great potential for 639 
future therapeutics against Gram-negative pathogens. Key to future drug development in this 640 
area is repeating the success of the early to mid-20th century boom in antibiotic discovery. 641 
Bacteria are the most successful and innovative organisms on earth. Just as mother nature 642 
provides infectious microorganisms with the tools for survival, so too does she hold the key 643 
to solving the riddle of antimicrobial resistance. Scientists at Northeastern University Boston 644 
recently uncovered a new antibiotic molecule, teixobactin, produced by bacteria (Eleftheria 645 
terrae) present in soil. This molecule displays activity against Methicillin resistant 646 
Staphylococcus aureus and bacteria implicated in tuberculosis infections but lacks effective 647 
action against Gram-negatives. Similarly, “The Drugs from Dirt” project is a worldwide 648 
initiative aiming to harness the capability of soil bacteria and the antimicrobial compounds 649 
they produce. Microorganisms have long been known to be capable of producing such 650 
molecules. They serve as weapons for survival facilitating destruction of competitive 651 
microbial species and enabling survival in natural environments. Therefore their ability to 652 
produce Gram-negative selective compounds seems logical. Chemically the most promising 653 
of these naturally occurring compounds are peptides. Present throughout the animal and plant 654 
kingdoms as part of the immune response, peptides are one the most effective molecules in 655 
the fight against multi-drug resistant infection. Most promising, and in contrast with many 656 
current therapies, is their ability to attack infectious microorganisms by multiple mechanisms. 657 
The ability of bacteria to develop resistance against peptides is thus significantly limited. A 658 
mining-like approach is an encouraging strategy to unlock innovative peptide antimicrobials 659 
and may eventually lead to an era of discovery and a 21st century “antimicrobial rush.” 660 
Creating patient friendly therapies, for example oral dose formulations, from the most 661 
promising of these molecules will require input from experts within the pharmaceutical 662 
industry, healthcare workers and patients themselves. Only this way will such discoveries 663 
create true value and easily translate from the laboratory to hospitals, communities and the 664 
patient. 665 
 666 
Executive summary  667 
Introduction 668 
• Resistance to standard therapies employed in Gram-negative bacterial infection have 669 
increased to worrying levels over the last 30 years.   670 
• There are a multitude of reasons for the declining clinical translation of antimicrobial 671 
drugs in the past 20 years, including safety issues highlighted in clinical trials and 672 
concerns from the pharmaceutical industry that investment in novel therapies would not 673 
warrant a significant financial return. 674 
 675 
The Gram-negative outer membrane as a barrier to therapy 676 
I. Bacterial cell wall structure 677 
• The outer membrane of Gram-negative bacteria acts as a selective barrier to the entry of a 678 
vast range of currently available antibiotic molecules.  679 
II. Antimicrobial resistance mechanisms of Gram-negative bacterial cell wall  680 
• Alteration of lipid A, phospholipids and/or protein composition of the outer membrane 681 
contribute to increased resistance to antimicrobial/antiseptic molecules that target the 682 
bacterial cell membrane. 683 
 684 
Strategies for extending therapeutic activity against Gram-negatives  685 
I. Antimicrobial peptides 686 
• Antimicrobial peptides exist throughout nature as mediators of the innate immune 687 
response. 688 
• Most cationic antimicrobial peptides target the bacterial cell membrane, leading to rapid 689 
cell lysis and bacterial death. They also possess multiple intracellular targets. 690 
• Cyclic antimicrobial peptides, which are among the most promising antimicrobial agents, 691 
provide a starting point for designing low molecular mass anti-LPS compounds. 692 
II. Combinational antibiotic treatment for Gram-negative bacteria 693 
• Combination therapy is recommended for patients at high risk of being infected with 694 
multidrug-resistant Gram-negative bacteria, demonstrating lower mortality rates and 695 
improved clinical outcomes.  696 
III. The activity of silver against Gram-negative bacterial infection  697 
• Silver increases the permeability of Gram-negative bacterial membranes and can 698 
potentiate the activity of a broad range of antibiotics against these microorganisms. 699 
• Silver nanoparticles have attracted interest due to their potential applications within 700 
wound dressings, medical device coatings, and drug delivery. 701 
 702 
Specific methods to target Gram-negative pathogens 703 
I. Negating the biological effects of Gram-negative lipopolysaccharide 704 
• An important consideration when treating suspected or confirmed Gram-negative 705 
infection is preventing the biological effects of Gram-negative lipopolysaccharide. This 706 
potent molecule signals bacterial invasion and triggers defensive host responses to release 707 
pro-inflammatory mediators, cytokines, chemokines, and lipoproteins. 708 
II. Targeting disulfide bond formation by the bacterial DsbA-DsbB enzyme system of 709 
Gram-negative bacteria 710 
• DsbA-DsbB system in Gram-negative bacteria is a key target for the development of new 711 
drug molecules. Inhibition of disulfide bond formation has been demonstrated to prevent 712 
the assembly of key bacterial virulence factors.   713 
 714 
III. Inactivating Gram-negative efflux pumps  715 
• Inactivating Gram-negative efflux pumps has the potential to restore resistant antibiotics 716 
activity. 717 
 718 
Methods to extend the spectrum of activity of existing narrow spectrum Gram-positive 719 
antibiotics to Gram-negatives 720 
I. Fusogenic liposomes 721 
• Encapsulating narrow spectrum Gram-positive selective antibiotics within fusogenic 722 
liposomes has been shown to broaden their spectrum of activity to cover Gram-negative 723 
infections by enabling transversion across the outer membrane. 724 
II. Carbon and peptide nanotubes 725 
• Single-walled carbon nanotubes may be useful in molecules as future antimicrobials due 726 
to their inherent antimicrobial properties and ability to deliver existing and future 727 
antibiotic molecules via nanoparticle-based drug delivery. 728 
• Cyclic D, L-alpha peptides are able to selectively target bacterial cell membranes, 729 
including the outer membrane of Gram-negatives. They are able to self-assemble, 730 
forming peptide nanotubes with the potential to act as biofunctional nanomaterials and 731 
improve intracellular delivery of antibiotics. 732 
III. Targeting Gram-negative pathogens with an engineered phage lytic enzyme 733 
• Phage lytic enzymes can be engineered to cross the outer envelope of targeted Gram-734 
negative bacteria. This is achieved by production of a “hybrid lysin” and “artilysin” that 735 
have the ability to kill pathogenic Escherichia coli strains and Pseudomonas aeruginosa.  736 
 737 
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